HVTN 142 - Males 18-55
STUDY BASICS
Are you a man 18 to 55 years old and in good health? You may be eligible to participate in a research study to test an experimental vaccine against HIV. This study wants to see if the study vaccine is safe and how a person’s immune system responds to it. Compensation is provided.
STUDY PURPOSE
The purpose of this study is to see if the study vaccine is safe and how a person’s immune system responds to it.
This study hopes to answer several main questions:
- Is the study vaccine safe to give to people?
- Are people able to take the study vaccine without becoming too uncomfortable?
- How do people’s immune systems respond to the study vaccine? (Your immune system protects you from infections and diseases.)
- Does the virus used to make the study vaccine show up in people’s body fluids?
This study is testing an experimental HIV vaccine. The study vaccine is called VIR-1388.
COULD THIS STUDY BE RIGHT FOR YOU?
- Male age 18-55
- In overall good health
WHAT PARTICIPANTS CAN EXPECT
- 16-20 scheduled visits over approximately 12 months.
- Participants may be asked to come back for clinic visits for long term follow-up at 2 years and 3 years after their injection. Long term follow-up is optional.
IRB: SSU00213622
- Vir Biotechnology, Inc. - HVTN 142, A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV (Pro00070151)MEET THE RESEARCHER
![](/imagelibrary/getimagegrayscale?FileName=mchoudhary.png)
Madhu Choudhary
Madhu Choudhary is an Associate Professor in the Division of Infectious Diseases in the Department of Medicine at the University of Pittsburgh. A graduate of Maulana Azad Medical College, Dr. Choudhary’s research interests include HIV and viral hepatitis therapeutic clinical trials.